Verona Pharma Plc - ADR

NASDAQ:VRNA

91.53

+1.45 (+1.61%)

4:58:13 PM EDT: $90.60 -0.93 (-1.02%)

Market Cap (Intraday)	7.92B
Current PE	N/A
Forward PE	457.65
2yr Forward PE	77.57

See more stats

Estimates Current Quarter

Revenue	$95.31 Million
Adjusted EPS	$0.02

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Verona Pharma Plc - ADR Stock, NASDAQ:VRNA

3 More London Riverside, 3 More London Riverside, London, Greater London SE1 2RE

United Kingdom

Phone: +44.203.283.4200

Number of Employees: 209

http://www.veronapharma.com

Description

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.